The decision by the U.S. Health Resources & Services Administration (HRSA) to refer six drug manufacturers to the U.S. Health and Human Services Department of the Office of The Inspector General (HHS OIG) for refusing to offer 340B discounts to covered entities that use contract pharmacies drew praise from 340B provider groups and was roundly criticized by the drug companies and their primary lobbying group.
HRSA made the referrals of AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, United Therapeutics and Sanofi on Wednesday. If the HHS OIG opens an investigation as a result of the referral and finds wrongdoing, the companies could face very steep monetary penalties.
The decision by the U.S. Health Resources & Services Administration (HRSA) to refer six drug manufacturers to the U.S. Health and Human Services Department of the Office of The Inspector General (HHS OIG) for refusing to offer 340B discounts to covered entities that use contract pharmacies drew praise from 340B provider groups and was roundly criticized by the drug companies and their primary lobbying group.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
